Sheng-pu Pharmaceuticals

Shengpu Pharmaceuticals is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of RNA interference (RNAi) therapeutics. The company leverages its proprietary GalNAc-siRNA delivery platform and lipid-based delivery systems to target unmet medical needs in oncology, dermatology, and fibrosis. Its lead candidate, SNP-S102, is currently being evaluated in Phase 2 clinical trials for the treatment of hypertrophic scars, representing a novel approach to scar management. Shengpu's pipeline also includes programs for hepatocellular carcinoma and other chronic conditions, focusing on high-specificity gene silencing. The company aims to provide innovative, long-acting treatments by utilizing the precision of siRNA technology.